What is claimed is:

1. Use of an inhaled preparation of magnesium isoglycyrrhizinate in preparing drugs for treating chronic obstructive pulmonary disease, characterized in that the inhaled preparation is powder for inhalation or a liquid preparation for use in nebulizers, and further characterized in that the inhaled preparation delivers the magnesium isoglycyrrhizinate to lungs to exert a local or systemic effect, wherein

the powder for inhalation comprises: micronized magnesium isoglycyrrhizinate and one or more pharmaceutically acceptable carriers, wherein the magnesium isoglycyrrhizinate has a particle size of 0.5–10 μm, and the pharmaceutically acceptable carrier is ground lactose, sieved lactose or a mixture of sieved lactose and fine lactose, wherein the volume-based particle size distribution of the ground lactose ranges from 1 to 350 μm, the volume-based particle size distribution of the sieved lactose ranges from 1 to 200 μm, and the volume-based particle size distribution of the fine lactose ranges from 1 to 60 μm; and

the liquid preparation for use in a nebulizer comprises: magnesium isoglycyrrhizinate, an isotonicity adjusting agent, a pH adjusting agent, and water for injection, with the pH of 6.0–8.0, wherein the nebulizer is a continuous nebulizer or a quantitative nebulizer.

2. Use of an inhaled preparation of magnesium isoglycyrrhizinate in preparing expectorant, characterized in that the inhaled preparation is powder for inhalation or a liquid preparation for use in nebulizers, and further characterized in that the inhaled preparation delivers the magnesium isoglycyrrhizinate to lungs to exert a local or systemic effect, wherein

the powder for inhalation comprises: micronized magnesium isoglycyrrhizinate and one or more pharmaceutically acceptable carriers, wherein the magnesium isoglycyrrhizinate has a particle size of 0.5–10 μm, and the pharmaceutically acceptable carrier is ground lactose, sieved lactose or a mixture of sieved lactose and fine lactose, wherein the volume-based particle size distribution of the ground lactose ranges from 1 to 350 μm, the volume-based particle size distribution of the sieved lactose ranges from 1 to 200 μm, and the volume-based particle size distribution of the fine lactose ranges from 1 to 60 μm; and

the liquid preparation for use in a nebulizer comprises: magnesium isoglycyrrhizinate, an isotonicity adjusting agent, a pH adjusting agent, and water for injection, with the pH of 6.0–8.0, wherein the nebulizer is a continuous nebulizer or a quantitative nebulizer.

3. Use of an inhaled preparation of magnesium isoglycyrrhizinate in preparing drugs for treating chronic viral hepatitis by sequential therapy, characterized in that the inhaled preparation is powder for inhalation or a liquid preparation for use in nebulizers, and further characterized in that the inhaled preparation delivers the magnesium isoglycyrrhizinate to lungs to exert a local or systemic effect, wherein,

the powder for inhalation comprises: micronized magnesium isoglycyrrhizinate and

one or more pharmaceutically acceptable carriers, wherein the magnesium isoglycyrrhizinate has a particle size of 0.5–10 μm, and the pharmaceutically acceptable carrier is ground lactose, sieved lactose or a mixture of sieved lactose and fine lactose, wherein the volume-based particle size distribution of the ground lactose ranges from 1 to 350 μm, the volume-based particle size distribution of the sieved lactose ranges from 1 to 200 μm, and the volume-based particle size distribution of the fine lactose ranges from 1 to 60 μm; and

the liquid preparation for use in a nebulizer comprises: magnesium isoglycyrrhizinate, an isotonicity adjusting agent, a pH adjusting agent, and water for injection, with the pH of 6.0–8.0, wherein the nebulizer is a continuous nebulizer or a quantitative nebulizer.

4. The use according to any one of claims 1 to 3, characterized in that the magnesium isoglycyrrhizinate in the powder for inhalation has a particle size of 0.5–5 μm.

5. The use according to any one of claims 1 to 4, characterized in that the ground lactose has a particle size distribution of X_{50} < 30–110 μm, the sieve lactose has a particle size distribution of X_{50} < 35–115 μm, and the fine lactose has a particle size distribution of X_{90} < 45 μm.

6. The use according to any one of claims 1 to 5, characterized in that the micronized magnesium isoglycyrrhizinate and the carrier are mixed and filled into a capsule or a bubble-cap.

7. The use according to claim 6, characterized in that each capsule or bubble-cap comprises 1–50 mg of micronized magnesium isoglycyrrhizinate and 0–50 mg of lactose.

8. The use according to claim 6 or claim 7, characterized in that each capsule or bubble-cap comprises 1–30 mg of micronized magnesium isoglycyrrhizinate and 1–40 mg of lactose.

9. The use according to any one of claims 1 to 8, characterized in that the powder for inhalation further comprises: one or more pharmaceutically acceptable additives.

10. The use according to claim 9, characterized in that the pharmaceutically acceptable additive is a surfactant and/or a lubricant, wherein the surfactant and/or lubricant is magnesium stearate and/or phospholipid.

11. The use according to any one of claims 1 to 3, characterized in that the amount of the magnesium isoglycyrrhizinate is from 0.1 mg/ml to 5 mg/ml.

12. The use according to claim 11, characterized in that the amount of the magnesium isoglycyrrhizinate is from 0.1 mg/ml to 2.5 mg/ml.

13. The use according to any one of claims 1 to 3, characterized in that the isotonicity adjusting agent is one or more selected from the group consisting of glucose, sodium chloride, potassium chloride, and mannitol.

14. The use according to any one of claims 1 to 3, characterized in that the pH

adjusting agent is one or more selected from the group consisting of sodium hydroxide, ammonium hydroxide, hydrochloric acid, sodium carbonate, sodium bicarbonate, dilute sulfuric acid, citric acid, sodium citrate, acetic acid, tartaric acid, sodium acetate or disodium hydrogen phosphate.

15. The use according to any one of claims 1 to 3 or 11 to 14, characterized in that the pH is 6.5-7.0.

16. The use according to any one of claims 1 to 3 or 11 to 15, characterized in that the inhaled preparation is packaged in a single dose in a package size of 1 ml, 2 ml or 5 ml.

17. The use according to any one of claims 1 to 16, characterized in that the administration frequency of the inhaled preparation to a subject is selected from: up to three times a day, up to twice a day, up to once a day and up to once every other day.